
Depomed hires Kyalin chief executive
pharmafile | July 21, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Depomed, Srinivas Rao
California-based speciality pharma firm Depomed has appointed Dr Srinivas Rao as its chief medical officer (CMO) and senior VP.
Rao was the founder and chief executive of Kyalin Biosciences, a privately held biotech company, from its formation in 2011 through to its sale to Retrophin in 2013.
In 2014 Rao served as executive VP and head of Neuroscience at Retrophin. In the three years prior Rao also was the CMO and chief scientific officer (CSO) for three companies through his association with Avalon Ventures.
Prior to that from 2001 he was CSO of Cypress Bioscience where he had a broad range of responsibilities, from business matters through to clinical development.
“We are delighted to have Srini join us as chief medical officer,” says Jim Schoeneck, president and chief executive at Depomed. “His deep expertise in the areas of pain and neurology and his experience in in-licensing and directing the clinical development and approval of medicines to treat important CNS conditions make him a great fit for Depomed as we seek to expand our franchise in pain and central nervous system diseases.”
Related Content

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of …

Depomed criticised by investors and urged to explore potential sale
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, …

Horizon Pharma receives third rejection from Depomed
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy …






